

The molecular basis of the genetic mosaicism in hereditary tyrosinemia (HT1)

**ETRESIA VAN DYK (M.Sc.)
12126497**

Thesis submitted for the degree Doctor of Philosophy in Biochemistry at the
Potchefstroom campus of the North-West University

Promoter: Prof P.J. Pretorius

July 2011

GENADE, ALLES NET GENADE

-Totius

Abstract

Hereditary tyrosinemia type 1 (HT1) is an autosomal recessive disorder of the tyrosine degradation pathway. The defective fumarylacetoacetate hydrolase enzyme causes the accumulation of upstream metabolites such as fumarylacetoacetate (FAA), maleylacetoacetate (MAA), succinylacetone (SA) and *p*-hydroxyphenylpyruvic acid (pHPPA). *In vitro* and *in vivo* studies showed that the accumulation of these metabolites are detrimental to cell homeostasis, by inducing cell cycle arrest, apoptosis, and endoplasmic reticulum stress, depleting GSH, inhibiting DNA ligase, causing chromosomal instability, etc. For *in vivo* studies different models of HT1 were developed. Most notably was the *fah* deficient mouse, whose neonatally lethal phenotype is rescued by the administration of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). Although, this model most closely resembles the human phenotype with elevated tyrosine levels and the development of hepatocellular carcinoma (HCC), the model is not human genome based.

Both the *in vitro* and *in vivo* studies suggested that DNA repair is affected in HT1. However, it is not yet clear which DNA repair mechanisms are affected and if only protein functionality is affected, or if expression of DNA repair proteins are also affected.

Characteristic of HT1 is the high prevalence of HCC and the presence of liver mosaicism. The liver mosaicism observed in HT1 patients are the result of reversion of the inherited mutation to wild-type. The general consensus is that the reversion is the result of a true back mutation. However, the mechanism underlying the back mutation is still unresolved.

It was suggested that cancer develops either through a chromosomal instability mutator phenotype, a microsatellite instability mutator phenotype, or a point mutation instability mutator phenotype. In HT1 only chromosomal instability was reported.

The aims of this study were to contribute to the understanding of the molecular basis of the genetic mosaicism in hereditary tyrosinemia type 1. More specifically, determine whether base- and nucleotide DNA repair mechanisms are affected and to what extent, and to determine if microsatellite instability is found in HT1. To achieve these aims, a parallel approach was followed: i.e. to develop a HT1 hepatic cell model and to use HT1 related models and HT1 patient material. To assess the molecular basis of the genetic mosaicism in HT1, the comet assay, gene expression assays, microsatellite instability assays, high resolution melting and dideoxy sequencing techniques were employed.

Results from the comet assay showed that the HT1 accumulating metabolites, SA and pHPPA, decreased the capacity of cells for base- and nucleotide excision repair. Gene expression assays showed that short term exposure to SA and/or pHPPA do not affect expression of *hOGG1* or *ERCC1*. The expression of these genes were, however, low in HT1 patient samples. Microsatellite instability assays showed allelic imbalance on chromosome 7 of the mouse genome, and microsatellite instability in the lymphocytes of HT1 patients. Although high resolution melt and sequencing results did not reveal any *de novo* mutations in *fah* or *hprt1*, the appearance of *de novo* mutations on other parts of the genome can not be ruled out.

To conclude, results presented in this thesis, for the first time show that in HT1 the initiating proteins of the base- and nucleotide repair mechanisms are affected, the gene expression of DNA repair proteins are low, and microsatellite instability is found in HT1. By contributing to the elucidation of the mechanism underlying the development of HT1-associated HCC, and providing evidence for the development of a mutator phenotype, the results presented in this thesis contributes to the understanding of the molecular mechanisms underlying the genetic mosaicism in HT1. In addition to these contributions, a hypothesis is posited, which suggests that a point mutation instability (PIN) mutator phenotype is the mechanism underlying the mutation reversions seen in HT1.

Samevatting

Die onderwerp van hierdie studie is: “Die molekulêre agtergrond van die genetiese mosaïek in oorerflike tirosinemie (HT1)”. Oorerflike tirosinemie tipe 1 (HT1) is 'n outosomale resessiewe versteuring van die tirosien-katabolisme. Die defektiewe fumarielasetoasetaat-hidrolase ensiem veroorsaak dat intermediêre metaboliete soos fumarylasetoasetaat, maleïelasetoasetaat, suksinielasetoon (SA) en *p*-hidroksiefenielpiruvaat (pHPPA) ophoop. Beide *in vitro* en *in vivo* studies het getoon dat die opeenhoping van hierdie metaboliete nadelig is vir sel-homeostase deur onder andere staking van die selsiklus, apoptose, en endoplasmiese retikulum stres te induseer, glutatioonvlakke uit te put, DNS-ligase te inhibeer en chromosomale-onstabiliteit te veroorsaak. Vir *in vivo* studies is verskillende HT1-modelle ontwikkel, waarvan die belangrikste die *fah*-gebrekkige muis is, en die neonatale fenotipe van hierdie model word grootliks beskerm deur behandeling met NTBC. Alhoewel hierdie model baie ooreenstem met die menslike fenotipe, met verhoogde tirosien-vlakke en die ontwikkeling van HCC, is die model nie op die menslike genoom gebaseer nie.

Beide *in vitro* en *in vivo* studies dui daarop dat DNS-herstel benadeel word in HT1, maar dit is egter nog nie duidelik watter DNS-herstelmeganismes geraak word nie, en of slegs proteïenfunsie, of uitdrukking van DNS-herstelproteïene ook geraak word nie.

Kenmerkend van HT1 is die hoë voorkoms van heptosellulêre karsinoom (HCC) en die teenwoordigheid van 'n lewermosaïek. Die lewermosaïek wat in HT1 pasiënte waargeneem word, is die gevolg van die omkeer van die oorgeërfde mutasie tot die wilde-tipe. Die algemene konsensus is dat hierdie omkeer die resultaat is van 'n ware terugmutasie. Die meganisme onderliggend hieraan is egter nog onbekend.

Die algemene oortuiging is dat kanker kan ontwikkel óf deur 'n chromosomale-onstabiliteit gegenereerde mutasie-fenotipe óf 'n mikrosatelliet-onstabiliteit genereerde mutasie-fenotipe. In HT1 is daar al chromosomale-onstabiliteit waargeneem, maar nie mikrosatelliet-onstabiliteit nie.

Die doel van hierdie studie was om by te dra tot die ontrafeling van die molekulêre basis van die genetiese mosaïek wat voorkom in tirosinemie tipe 1. Meer spesifiek, om vas te stel of basis- en nukleotied DNS-herstelmeganismes beïnvloed word en tot in watter mate, en om te bepaal of mikrosatelliet-onstabiliteit in HT1 waargeneem word. Om hierdie doelwitte te bereik is 'n parallelle benadering gevolg. Aan die een kant is 'n HT1 heptiese sel model ontwikkel deur RNS-tussenkoms tegnologie, en aan die ander kant is van HT1-verwante modelle en HT1-

pasiëntmateriaal gebruik gemaak. Om te molekulêre basis van die genetiese mosaïek in HT1 te bepaal is die volgende analyses uitgevoer: die komeet analise, geenuitdrukking analise, mikrosatelliet-onstabiele analise, hoë resolusie smelt, en volgordebepalings.

Resultate van die komeet analise het getoon dat die HT1-akkumulerende metaboliete, SA en pHPPA, die vermoë van selle vir basis- en nukleotied DNS-herstel verlaag. Geenuitdrukking analises het getoon dat die korttermyn blootstelling aan SA en/of pHPPA nie die uitdrukking van *hOGG1* of *ERCC1* beïnvloed nie. Die uitdrukking van hierdie gene is egter aansienlik verlaag in HT1-pasiëntmateriaal. Mikrosatelliet-onstabiele analises het getoon dat alleliese-wanbalans in chromosoom 7 van die muis genoom, en mikrosatelliet-onstabiele in die limfosiete van HT1-pasiënte voorkom. Alhoewel in die hoë resolusie smelt en volgordebepalings resultate *de novo* mutasies in *fah* of *hprt1* nie waargeneem is nie, kan die voorkoms van *de novo* mutasies in ander dele van die genoom nie uitgesluit word nie.

Die resultate wat in hierdie proefskrif vervat is, wys vir die eerste keer dat in HT1, basis- en nukleotied DNS-herstelmeganismes geraak word, die geen uitdrukking van DNS-herstelproteïene verlaag is, en dat mikrosatelliet-onstabiele in HT1 waargeneem word. Deur by te dra tot die toeligting van die meganismes onderliggend aan die ontwikkeling van HT1-verwante HCC, en die verskaffing van bewyse vir die ontwikkeling van 'n mutasiegenererende fenotipe, dra die resultate by tot die begrip van die molekulêre meganismes onderliggend aan die genetiese mosaïek gesien eie aan HT1. Bo en behalwe vir hierdie bydraes, is 'n hipotese gemaak dat 'n puntmutasie-onstabiele (PIN) mutasiegenererende fenotipe die meganisme onderliggend is aan die mutasie omkerings wat in HT1 mag plaasvind.

Keywords

Hereditary tyrosinemia type1; Mosaicism; Hepatocellular carcinoma; DNA repair; Genome instability; Mutator phenotype

Table of content

Abstract.....	i
Samevatting.....	iii
Keywords	v
Table of content	vi
List of symbols	viii
List of abbreviations.....	ix
List of figures	xiv
List of tables	xv
Chapter 1: Introduction.....	1
Chapter 2: Literature review.....	4
2.1 Hereditary tyrosinemia type 1	4
2.1.1 Introduction to inherited metabolic disorders	4
2.1.2 Inherited disorders of the tyrosine catabolism	5
2.1.3 Hereditary tyrosinemia type 1.....	7
2.1.3.1 General considerations	7
2.1.3.2 Diagnosis and treatment	10
2.1.3.3 Genetics of FAH.....	10
2.1.3.4 Mutation reversion.....	11
2.1.3.5 Accumulating metabolites.....	12
2.1.3.6 HT1 models.....	14
2.2 Mosaicism.....	15
2.2.1 Introduction to mosaicism	15
2.2.2 Mosaicism in HT1	16
2.3 DNA repair.....	17
2.3.1 Introduction to DNA repair mechanisms.....	17
2.3.2 DNA excision repair mechanisms.....	17
2.3.2.1 Base excision repair	18
2.3.2.2 Nucleotide excision repair	18
2.3.2.3 Mismatch repair (MMR).....	19
2.3.3 Consequences of defective DNA repair	19
2.4 Summary	20
Chapter 3: HT1 hepatic cell model	23
3.1 Development of a HT1 hepatic cell model.....	23
3.1.1 shRNA oligonucleotide design, acquisition and annealing.....	24

3.1.2 Cloning shRNAs into pSIREN-RetroQ-Tet vector	25
3.1.3 Pilot experiments	26
3.1.4 Development of a single-stable ptTS expressing cell line	26
3.1.5 Developing a double-stable cell line	27
3.2 Future considerations	33
Chapter 4: Methodology	35
4.1 Cell cultures	35
4.2 DNA and RNA samples	35
4.3 Comet assay modified for BER and NER	36
4.4 Gene expression	37
4.4.1 RT-PCR	37
4.4.2 Gene expression	38
4.5 Microsatellite analysis with Agilent 2100 Bioanalyzer	39
4.6 High resolution melting	40
4.7 PCR and sequencing	41
Chapter 5: Results and discussion	44
5.1 DNA damage and repair	44
5.2 Gene expression profiles	46
5.3 Genome stability	53
5.4 Point mutation instability	61
Chapter 6: Paper 1	69
Chapter 7: Paper 2	75
Chapter 8: Summary and conclusion	82
Chapter 9: Paper 3	88
References	94
Appendix A: Vector maps	108
Appendix B	110
Appendix C	111
Appendix D	112
Appendix E: Conference Abstract	114

List of symbols

°C:	Degrees Celsius
μl:	Microlitre
μM:	Micromolar
α:	Alpha
β:	Beta
Δ or δ:	Delta
ε:	Epsilon
%:	Percentage
φ:	Phi

List of abbreviations

A:

A:	Adenine
ANON:	Anonymous
ANOVA:	Analysis of variance
AP:	Abasic site
APC:	Adenomatous polyposis coli
ATCC:	American tissue culture company
ATP:	Adenosine triphosphate

B:

BER:	Base excision repair
BiP:	Binding immunoglobulin protein
bp:	Basepair
BRCA1:	Breast cancer 1
BSA:	Bovine serum albumin

C:

C:	Cytosine
CAF:	Central Analytical Facility
cDNA:	Complementary DNA
CHOP:	CEBP homologous protein
CIN:	Chromosomal instability
cM:	Centi-Morgan
COLD-PCR:	Co-amplification at lower denaturation temperature-PCR
CSA:	Cockayne syndrome group A
CSB:	Cockayne syndrome group B
Cu:	Copper

D:

DDB:	DNA damage binding protein
ddH ₂ O:	Double distilled water
DMEM:	Dulbecco's modified eagles medium
DMSO:	Dimethylsulfoxide
DNA:	Deoxyribonucleic acid
DNMT1:	DNA methyltransferase 1
dNTP:	Deoxyribonucleotide triphosphate
DOPA:	Dihydroxyphenylalanine

DOVA:	4,5-Dioxovaleric acid
Dox:	Doxycycline
DSB's:	Double strand breaks
DTT:	Dithiothreitol
E:	
EDTA:	Ethylenediamine tetraacetic acid
EGTA:	Ethylene glycol-bis(β -aminoethyl ether) N,N,N',N'-tetraacetic acid
eIF2 α :	Eukaryotic translation factor 2 alpha
ENU:	<i>N</i> -ethyl- <i>N</i> -nitrosourea
ERCC1:	Excision repair cross-complementing rodent repair deficiency, complementation group 1
ERK:	Extra cellular signal-regulated protein kinase
<i>Et al</i> :	Et Alii/Alia (Latin: And others)
EtBr:	Ethidium Bromide
EtOH:	Ethanol
EXO1:	Exonuclease 1
F:	
FA:	Fumarylacetone
FAA:	Fumarylacetoacetate
FAH:	Fumarylacetoacetate hydrolase
FBS:	Fetal bovine serum
Fe:	Iron
FPG:	Formamido-pyrimidine glycosylase
Fwd:	Forward
G:	
g:	Gram
<i>g</i> :	Gravitational force
G:	Guanine
Gas:	Growth arrest specific 2
GGR:	Global genomic repair
GRP17:	Gadd-related protein 17 kDa
GSH:	Glutathione
GSTZ1-1:	Glutathion transferase zeta
H:	
h:	Hours
H ₂ O:	Water
H ₂ O ₂ :	Hydrogen peroxide
HCC:	Hepatocellular carcinoma

HEPES:	N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic Acid
HGD:	homogentisate-1,2-dioxygenase
HMPA:	High melting point agarose
HPD:	4-hydroxyphenylpyruvate dioxygenase
HPRT1:	Hypoxanthine phosphoribosyltransferase 1
HR:	Homologous repair
HRM:	High resolution melt
HT1:	Hereditary tyrosinemia 1
I:	
i.e.:	id est (that is)
K:	
KCl:	Potassiumchloride
(KH ₂ P)O ₄ :	Potassiumdihydrogen orthophosphate
L:	
LMPA:	Low melting point agarose
M:	
3-meA:	3-Methyladenine
7-meG:	7-Methylguanine
M:	Molar
MA:	Maleylacetone
MAA:	Maleylacetoacetate
MEM:	Minimum essential medium Eagle
mg:	Milligram
min:	Minutes
miRNA:	Micro RNA
ml:	Millilitre
MLH:	MutL homolog
mM:	Millimolar
MMLV:	Moloney Murine Leukemia Virus Reverse Transcriptase
MMR:	Mismatch repair
mRNA:	Messenger RNA
MSH:	MutS homolog
MSI:	Microsatellite instability
MutL α :	MLH1•PMS2 heterodimer
MutS α :	MSH2•MSH6 heterodimer

N:

N.A.	Not available
NaCl:	Sodium chloride
NaHCO ₃ :	Sodium bicarbonate
NaOH:	Sodium hydroxide
NCI:	National Cancer Institute
N.D.:	Not done
NER:	Nucleotide excision repair
ng:	Nanogram
NHEJ:	Non-homologous end joining
NTBC :	2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione

O:

OH:	Hydroxy radical
8-oxoG:	8-Oxoguanine

P:

PAGE:	Polyacrylamide gel electrophoresis
PBS:	Phosphate buffered saline
PCR:	Polymerase chain reaction
pH:	Potential of Hydrogen
pHPAA:	p-Hydroxyphenylacetic acid
pHPLA:	p-Hydroxyphenyllactic acid
pHPPA :	p-Hydroxyphenylpyruvic acid
PIN:	Point mutation instability
PKU:	Phenylketonuria
PMS2:	postmeiotic segregation increased 2

R:

Ref:	Reference
Rev:	Reverse
RFLP:	Restriction fragment length polymorphism
RNA:	Ribonucleic acid
RNAi:	RNA interference
RNAPII:	RNA polymerase II
ROS:	Reactive oxygen species
RPA:	Replication protein
RPM:	Revolutions per minute
RQ:	Relative quantification
rRNA:	Ribosomal RNA
RT-PCR:	Reverse transcription polymerase chain reaction

S:

SA:	Succinylacetone
SAA:	Succinylacetoacetic acid
SCGE:	Single cell gel electrophoresis
sec:	Seconds
SFM:	Serum free medium
shRNA:	Short hairpin RNA
siRNA:	Small interfering RNA
SOC:	Super optimal broth with catabolite repression
SSB:	Single strand break

T:

T:	Thymine
T _c :	Critical melting temperature
TCR:	Transcription coupled repair
Tet:	Tetracycline
TFIIH:	Transcription factor II H
T _m :	Melting temperature
Tris-HCl:	2-Amino-2-(hydroxymethyl)-1,3-propandiol-hydrochloride
tTS:	Tetracycline-controlled transcriptional suppressor

U:

U:	Uracil
U:	Units
UV:	Ultra violet

X:

XPA:	Xeroderma pigmentosum, complementation group A
XPC:	Xeroderma pigmentosum, complementation group C
XPF:	Xeroderma pigmentosum, complementation group F
XPG:	Xeroderma pigmentosum, complementation group G
XRCC1:	X-ray repair complementing defective repair in Chinese hamster cells 1

List of figures

Figure 2-1. Tyrosine catabolism.	7
Figure 2-2. Schematic depiction of positions of mutations occurring in the <i>fah</i> gene.	9
Figure 3-1. Efficiency of transfection with FuGENE®.	28
Figure 3-2. Expression of <i>fah</i> by HepG2 cells after transient transfection with each of the shRNA constructs.	29
Figure 5-1. Comet assay results of recuperation time allowed after harvesting of HepG2 cells.	45
Figure 5-2. Expression of <i>hOGG1</i> by HepG2 cells after exposure to a combination of 50 µM SA and 100 µM pHPPA.	48
Figure 5-3. Expression of <i>ERCC1</i> by Hepg2 cells after exposure to a combination of 50 µM SA and 100 µM pHPPA.	49
Figure 5-4. Expression of <i>hOGG1</i> and <i>ERCC1</i> by HepG2 cells after exposure to SA or pHPPA seperately.	50
Figure 5-5. Expression of <i>fah</i> , <i>hOGG1</i> and <i>ERCC1</i> by control and patient primary lymphocytes.	54
Figure 5-7. Electrophoretograms of the different microsatellite markers.	56
Figure 5-8. Microsatellite analysis of the five microsatellite markers as recommended by the Bethesda panel.	57
Figure 5-9. DNA methylation in control and HT1 patients.	59
Figure 5-10. Position of Lesch-Nyhan disease causing mutations on the human <i>hprt1</i> gene.	62
Figure 5-11. Fluorescence-normalised melting data from HRM of human <i>fah</i> amplicons.	62
Figure 5-12. Multiple aligned <i>fah</i> sequencing results.	63
Figure 5-13. HRM results of the <i>fah</i> fragment, amplified by COLD-PCR.	64
Figure 5-14. Fluorescence-normalised melting data from HRM of human <i>hprt1</i> amplicons.	65
Figure 5-15. Multiple aligned human <i>hprt1</i> sequencing results.	65
Figure 5-16. HRM results from HPP4 fragment of mouse <i>hprt1</i>	66
Figure 5-17. Multiple aligned mouse <i>hprt1</i> sequencing results after conventional PCR.	67
Figure 5-18. Multiple aligned mouse <i>hprt1</i> sequencing results after COLD-PCR.	67
Figure A-1. RNAi-Ready pSIREN-RetroQ-TetP vector map.	108
Figure A-2. ptTS-Neo vector map.	108
Figure A-3. pEGFP-N1 vector map.	109
Figure A-4. pEZSeq vector map.	109
Figure C-1. HRM results from HPP1 fragment of mouse <i>hprt1</i>	111
Figure C-2. HRM results from HPP5 fragment of mouse <i>hprt1</i>	111

List of tables

Table 2-1. Summary of the inborn errors of metabolism of the tyrosine degradation pathway.	6
Table 2-2. Summary of the observed mutation reversions and their effects as seen in HT1.	12
Table 3-1. Sequence information of the four shRNAs designed for <i>fah</i> knock-down.	24
Table 3-2. Percentage knock-down of <i>fah</i> achieved in HepG2tTS cell lines 10 and 12.	31
Table 3-3. Percentage knock-down of <i>fah</i> by different colonies after incubation in different growth media.	32
Table 5-1. Motivation for use of the specific genes of interest.	47
Table 5-2. Information on microsatellite markers used for MSI testing in mouse DNA.	54
Table 5-3. Microsatellite repeat motifs.	55